Malgorzata Wojciechowska

Olsztyn, WN, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

The Role of Lifestyle and Environmental Factors in the Pathogenesis of Multiple Myeloma.

The Role of Lifestyle and Environmental Factors in the Pathogenesis of Multiple Myeloma.

Journal: European journal of haematology

Published: August 24, 2024

Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.

Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 20, 2023

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.

Journal: Anticancer research

Published: May 17, 2020

Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).

Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).

Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University

Published: June 15, 2019

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.

Journal: Advances in medical sciences

Published: August 21, 2018

Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).

Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).

Journal: European journal of haematology

Published: December 16, 2017

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).

Journal: Leukemia & lymphoma

Published: March 11, 2017

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Journal: British journal of haematology

Published: May 03, 2016

Unusual manifestation of crystalline light chain tubulopathy in patient with multiple myeloma: case report and review of the literature.

Unusual manifestation of crystalline light chain tubulopathy in patient with multiple myeloma: case report and review of the literature.

Journal: Renal failure

Published: February 12, 2014

Showing 1-9 of 9

Last Updated: 09/26/2026